Compare Moody's Corporation (MCO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Neurocrine Biosciences Inc — how do they compare? Moody's Corporation trades at $458.7 (market cap $79.44B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Moody's Corporation is far larger — about 5.5× Neurocrine Biosciences Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MCO | NBIX | |
|---|---|---|
Market Cap | $79.44B | $14.36B |
Volume | 526,684 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $539.61 | $185.50 |
52-Week Low | $412.23 | $123.10 |
Typical Hold Time | 132 Days | 23 Days |
Enterprise Value | $85.46B | $14.37B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $449.63, down 0.59% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, while net income margins expanded to 34.25%. Recent developments include strategic partnerships and board appointments, supporting the company's market leadership in credit analytics.
The investment outlook is positive given Moody's robust profitability, high ROE of 80.15%, and analyst consensus price target of $536.40 (19% upside). Risks include high valuation multiples (P/E 28.53, P/S 9.79) and exposure to economic cycles affecting credit demand. Institutional sentiment remains bullish with 56% buy ratings, though technical indicators suggest near-term consolidation near support at $440.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
